Pharmacokinetics/Pharmacodynamics of Nitroglycerin in pediatric pulmonary hypertension with congenital heart disease

Pharmacokinetics/Pharmacodynamics of Nitroglycerin in pediatric pulmonary hypertension with congenital heart disease - PK/PD of NTG in pediatric pulmonary hypertension

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026382

Enrollment

Registered

2017-03-15

Start date

2017-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric congenital heart disease

Interventions

Continuous intravenous infusion of NTG starts at 2 microg/kg/min when cardiopulmonary bypass is weaned. In PICU, dose of NTG will increase by 1 or 2 microg/kg/min depending on a pulmonary arterial pre

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children who will undergo an operation with pulmonary hypertension in congenital heart disease

Exclusion criteria

Exclusion criteria: 1) Palliated operation and single ventricle cases 2) Who are regarded as unsuitable by a doctor

Design outcomes

Primary

Measure	Time frame
Therapeutic window of NTG	—

Secondary

Measure	Time frame
Relationship between efficiency and adverse effect, and NTG concentration in blood	—

Countries

Japan

Contacts

Public ContactTatsuya Nagano

Jichi Children's Medical Center Tochigi, Jichi Medical University Department of Pediatric intensive care and Anesthesia

tnagano@jichi.ac.jp0285-58-7716

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026